Clinical Trials
25 trialsA Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL
GlaxoSmithKline
A Phase 2 Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
Guangzhou Lupeng Pharmaceutical Company LTD.
Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Sun Yat-sen University
ALT-101
Allterum Therapeutics, Inc
A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy
Fondazione Italiana Linfomi - ETS
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma
Shanghai Jiao Tong University School of Medicine
CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation
Affiliated Hospital to Academy of Military Medical Sciences
EpiRev-NKT
Fudan University
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ascentage Pharma Group Inc.
Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Tongji Hospital
A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
Affiliated Hospital of Jiangsu University
A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies
Affiliated Hospital of Jiangsu University
BaseCAR-01
University Hospital, Basel, Switzerland
Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)
Sun Yat-sen University
A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies
Biotroy Therapeutics
HEM-iSMART E
Princess Maxima Center for Pediatric Oncology
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
Nationwide Children's Hospital
RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
The First Affiliated Hospital with Nanjing Medical University
WGc-043
Ruijin Hospital
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.
BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma
Dalian Medical University
CAR-T Therapy
Zhengzhou University
Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL
Ruijin Hospital
A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma
Changhai Hospital